A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

More in doublet therapy for mHSPC….potentially a new treatment option. Authors reported they are submitting to FDA so will see if this gets approved.

Read the full article here

Related Articles